Literature DB >> 23253475

Telomerase and the search for the end of cancer.

Simone Mocellin1, Karen A Pooley, Donato Nitti.   

Abstract

Many of the fundamental molecular mechanisms underlying tumor biology remain elusive and, thus, developing specific anticancer therapies remains a challenge. The recently discovered relationships identified among telomeres, telomerase, aging, and cancer have opened a new avenue in tumor biology research that may revolutionize anticancer therapy. This review summarizes the critical aspects of telomerase biology that underpin the development of novel telomerase-targeting therapies for malignant diseases, and special regard is given to the aspects of telomerase that make it such an appealing target, such as the widespread expression of telomerase in cancers. Despite significant progress, issues remain to be addressed before telomerase-based therapies are truly effective and we include critical discussion of the results obtained thus far.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23253475     DOI: 10.1016/j.molmed.2012.11.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  44 in total

Review 1.  Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.

Authors:  Karima Ait-Aissa; Johnathan D Ebben; Andrew O Kadlec; Andreas M Beyer
Journal:  Pharmacol Res       Date:  2016-07-06       Impact factor: 7.658

Review 2.  TERT Promoter Mutations in Thyroid Cancer.

Authors:  Ali S Alzahrani; Rawan Alsaadi; Avaniyapuram Kannan Murugan; Bakr Bin Sadiq
Journal:  Horm Cancer       Date:  2016-02-22       Impact factor: 3.869

3.  BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.

Authors:  Mingzhao Xing; Rengyun Liu; Xiaoli Liu; Avaniyapuram Kannan Murugan; Guangwu Zhu; Martha A Zeiger; Sara Pai; Justin Bishop
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

4.  Frequency of TERT promoter mutations in primary tumors of the liver.

Authors:  Alexander Quaas; Theresa Oldopp; Lars Tharun; Catina Klingenfeld; Till Krech; Guido Sauter; Tobias J Grob
Journal:  Virchows Arch       Date:  2014-09-30       Impact factor: 4.064

5.  TERT promoter mutations in thyroid cancer: growing evidence for a predictor of poor outcome.

Authors:  Jianliang Man; Norman Nicolson; Courtney Gibson; Tobias Carling
Journal:  Gland Surg       Date:  2019-06

6.  Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma.

Authors:  Xiaoli Liu; Guojun Wu; Yuan Shan; Christian Hartmann; Andreas von Deimling; Mingzhao Xing
Journal:  Cell Cycle       Date:  2013-04-19       Impact factor: 4.534

7.  Amarogentin Induces Apoptosis of Liver Cancer Cells via Upregulation of p53 and Downregulation of Human Telomerase Reverse Transcriptase in Mice.

Authors:  Chun Huang; Runqin Li; Yinglin Zhang; Jianping Gong
Journal:  Technol Cancer Res Treat       Date:  2016-07-11

8.  Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.

Authors:  Rengyun Liu; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2014-08-13       Impact factor: 5.678

9.  Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.

Authors:  Xiaoguang Shi; Rengyun Liu; Shen Qu; Guangwu Zhu; Justin Bishop; Xiaoli Liu; Hui Sun; Zhongyan Shan; Enhua Wang; Yahong Luo; Xianghong Yang; Jiajun Zhao; Jianling Du; Adel K El-Naggar; Weiping Teng; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2015-01-13       Impact factor: 5.958

10.  Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.

Authors:  G Mosoyan; T Kraus; F Ye; K Eng; J D Crispino; R Hoffman; C Iancu-Rubin
Journal:  Leukemia       Date:  2017-03-08       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.